so the course of action would apply to the majority of the patients, but some may not want to follow the recommendation. Because of this, conditional recommendations are preference sensitive and always warrant a shared decision-making approach. Due to the complexity of management of active PsA, not all clinical situations and choices could be depicted in this flow chart, and therefore we show only the key recommendations. For a complete list of recommendations, please refer to the Results section of the text. For the level of evidence supporting each recommendation, see Table 2 Very low Conditional recommendation based on very-low-quality evidence; may consider switching to a TNFi biologic and MTX combination therapy if the current TNFi biologic is infliximab. 12. Switch to an IL-17i biologic monotherapy over switching to an IL-17i biologic and MTX combination therapy (PICO 32) Very low Conditional recommendation based on very-low-quality evidence; may consider switching to an IL-17i